Latest & greatest articles for ketamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ketamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ketamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ketamine

41. Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression

Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression Ketamine as an adjunct to electroconvulsive therapy for treatment-resistant depression HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Ketamine as an adjunct (...) Description: Intravenous injection (IV) of ketamine hydrochloride as an adjunct to electroconvulsive therapy (ECT) is intended to reduce symptoms of depression more rapidly and to a greater extent than ECT alone in patients who have TRD. Controversy: Early evidence for the antidepressant effect of ketamine came from uncontrolled studies and TRD may have diverse causes and poor response rates that make it difficult to demonstrate whether or not ketamine treatment is effective. Key Questions: Does ketamine

2017 Health Technology Assessment (HTA) Database.

42. Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Full Text available with Trip Pro

Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) , Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Published: October, 2016 DOI: Abstract Background Both ketamine and methamphetamine have been used for studying the positive, negative, and cognitive symptoms, and dopaminergic and GABAergic dysfunction observed in acute schizophrenia. We aimed

2016 Lancet

43. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression Full Text available with Trip Pro

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression Ketamine, an N-methyl-d-aspartate glutamate receptor antagonist, has demonstrated a rapid-onset antidepressant effect in patients with treatment-resistant depression. This study evaluated the efficacy of twice- and thrice-weekly intravenous administration of ketamine in sustaining initial antidepressant effects in patients with treatment-resistant (...) depression.In a multicenter, double-blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receive either intravenous ketamine (0.5 mg/kg of body weight) or intravenous placebo, administered over 40 minutes, either two or three times weekly, for up to 4 weeks. Patients who discontinued double-blind treatment after at least 2 weeks for lack of efficacy could enter an optional 2-week open-label phase to receive ketamine with the same frequency as in the double-blind

2016 EvidenceUpdates Controlled trial quality: predicted high

44. Ketamine: stimulating antidepressant treatment? Full Text available with Trip Pro

Ketamine: stimulating antidepressant treatment? The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to ketamine's potential as an option for treating depression (...) and Intervention Network, Canadian Network for Mood and Anxiety Treatments, Canadian Psychiatric Association, Coast Capital Savings, Johnson and Johnson, Lundbeck, Lundbeck Institute, Pfizer, Servier, St. Jude Medical, Takeda University, Health Network Foundation, and Vancouver Coastal Health Research Institute. R.M. Investigator Janssen trials of esketamine; 'paid-for' ketamine clinic operated by Oxford Health NHS Foundation Trust - fees used to support the Trust. M.J.O. Consultant: Sunovion and Acadia

2016 BJPsych open

45. Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Full Text available with Trip Pro

Ketamine for treatment-resistant depression: recent developments and clinical applicationsEditor's Choice FREE Ketamine for treatment-resistant depression: recent developments and clinical applications | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ketamine for treatment-resistant depression: recent developments and clinical applications Article Text Clinical review Ketamine for treatment-resistant depression: recent developments

2016 Evidence-Based Mental Health

46. Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial Full Text available with Trip Pro

Low-dose ketamine improves pain relief in patients receiving intravenous opioids for acute pain in the emergency department: results of a randomized, double-blind, clinical trial Low-dose ketamine has been used perioperatively for pain control and may be a useful adjunct to intravenous (IV) opioids in the control of acute pain in the emergency department (ED). The aim of this study was to determine the effectiveness of low-dose ketamine as an adjunct to morphine versus standard care (...) ) morphine and normal saline placebo (standard care group), 2) morphine and 0.15 mg/kg ketamine (group 1), or 3) morphine and 0.3 mg/kg ketamine (group 2). Participants were assessed at 30, 60, and 120 minutes after study medication administration and received rescue analgesia as needed to target a 50% reduction in pain. The primary outcome measure of pain relief, or pain intensity reduction, was derived using the NRS and calculated as the summed pain-intensity (SPID) difference over 2 hours. The amount

2015 EvidenceUpdates Controlled trial quality: predicted high

47. Ketamine in outpatient arthroscopic shoulder surgery: Effects on postoperative pain, hemodynamic stability and process times. Full Text available with Trip Pro

Ketamine in outpatient arthroscopic shoulder surgery: Effects on postoperative pain, hemodynamic stability and process times. Pain after arthroscopic shoulder surgery is often severe, and establishing a pain treatment regimen that does not delay discharge can be challenging. The reported ability of ketamine to prevent opioid-induced hyperalgesia has not been investigated in this particular setting.300 adult patients scheduled for shoulder arthroscopy under general anesthesia were recruited (...) for this observational clinical trial and were allotted to either receive 1mg/kg IV bolus of ketamine before surgery (ketamine group, KG) or to a control group (CG) without ketamine. NRS pain scores were obtained on the operative day and on postoperative days 1 and 2 and compared between groups. Secondary variables were blood pressure, heart rate, process times, satisfaction with the anesthetic and unwanted effects.Pain severity did not differ significantly between the groups at any time. Propofol injection rate

2015 Open medicine (Warsaw, Poland) Controlled trial quality: uncertain

48. Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines

Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Ketamine for adult patients who have suffered painful and traumatic injuries: a Review of Clinical Effectiveness, Cost-Effectiveness, Safety and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One study failed

2014 Health Technology Assessment (HTA) Database.

49. Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness

Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness Intravenous ketamine for the treatment of pain syndromes: clinical effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Intravenous ketamine (...) for the treatment of pain syndromes: clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non

2014 Health Technology Assessment (HTA) Database.

50. Chronic pain: oral ketamine

Chronic pain: oral ketamine Chronic pain: or Chronic pain: oral k al ketamine etamine Evidence summary Published: 25 February 2014 nice.org.uk/guidance/esuom27 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in February 2014. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Two small, short-term (...) , randomised, placebo-controlled trials and 1 small case series of n-of-1 trials provide no good quality evidence for the use of oral ketamine to treat chronic pain in adults. Only 1 phase I pilot study in young people was identified but this was too small and short-term to draw any firm conclusions about the efficacy and safety of oral ketamine for treating chronic pain in young people. In the studies that reported safety, oral ketamine was frequently associated with adverse effects that often resulted

2014 National Institute for Health and Clinical Excellence - Advice

51. Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department (Abstract)

Randomized, Double-Blinded, Clinical Trial of Propofol, 1:1 Propofol/Ketamine, and 4:1 Propofol/Ketamine for Deep Procedural Sedation in the Emergency Department We compare the frequency of airway and respiratory adverse events leading to an intervention between propofol with 1:1 and 4:1 mixtures of propofol and ketamine (ketofol).We performed a randomized, double-blinded trial in which emergency department adults undergoing deep sedation received propofol, 1:1 propofol and ketamine, or 4:1 (...) propofol and ketamine. Our primary outcome was the frequency of airway and respiratory adverse events leading to an intervention. Other outcomes included sedation depth, efficacy, procedure and recovery time, patient satisfaction, pain, and procedural recall.Two hundred seventy-one subjects completed the trial, 90 receiving propofol, 85 receiving 1:1 propofol and ketamine, and 96 receiving 4:1 propofol and ketamine. Airway or respiratory adverse events leading to an intervention were similar between

2014 EvidenceUpdates Controlled trial quality: predicted high

52. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines

Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation CADTH. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Major Depressive Disorder (MDD)Current evidence has consistently shown that IV ketamine may improve symptoms scored by the MADRS and HAM-D scoring tools at 24 hours in patients with MDD. However, identifying which

2014 Health Technology Assessment (HTA) Database.

53. Intravenous Ketamine for the Treatment of Pain Syndromes

Intravenous Ketamine for the Treatment of Pain Syndromes TITLE: Intravenous Ketamine for the Treatment of Pain Syndromes: Clinical Effectiveness DATE: 07 June 2013 RESEARCH QUESTIONS 1. What is the clinical effectiveness of intravenous (IV) ketamine for the treatment of recalcitrant chronic regional pain syndrome? 2. What is the clinical effectiveness of IV ketamine for the treatment of fibromyalgia? 3. What is the clinical effectiveness of IV ketamine for the treatment of reflex sympathetic (...) dystrophy? KEY MESSAGE One systematic review, two randomized controlled trials, and four non-randomized studies were identified regarding the clinical effectiveness of intravenous (IV) ketamine for the treatment of chronic regional pain syndrome. No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness of IV ketamine for the treatment of fibromyalgia or reflex sympathetic dystrophy. METHODS

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

54. Opioid-sparing effect of preemptive bolus low-dose ketamine for moderate sedation in opioid abusers undergoing extracorporeal shock wave lithotripsy: a randomized clinical trial Full Text available with Trip Pro

Opioid-sparing effect of preemptive bolus low-dose ketamine for moderate sedation in opioid abusers undergoing extracorporeal shock wave lithotripsy: a randomized clinical trial Ketamine has been used as part of a multimodal analgesia regime in opioid abusers undergoing general anesthesia. We studied the opioid-sparing effect of a very low-dose bolus of ketamine as part of moderate sedation for opioid abuse patients undergoing extracorporeal shock wave lithotripsy.In this randomized, placebo (...) -controlled clinical trial, 190 opioid abusers were enrolled. They were stratified into 2 blocks based on their daily opioid consumption. Both blocks were then randomized to receive 0.1 mg/kg IV ketamine (group K) or placebo (group P). Lithotripsy was performed under moderate sedation with intermittent bolus doses of remifentanil (0.2 µg/kg) to alleviate pain. The total remifentanil dose (primary outcome) and respiratory adverse events (secondary outcome) were compared in the 2 groups.Remifentanil

2013 EvidenceUpdates Controlled trial quality: predicted high

55. Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children?

Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children? Systematic Review Snapshot TAKE-HOME MESSAGE Limited data from a single randomized controlled trial do not support the routine use of ketamine for children with acute asthma exacerbations that are unresponsive to initial aerosolized b 2 -agonist or steroids. Is Ketamine Effective for the Management of Acute Asthma Exacerbations in Children? EBEM Commentators Randolph P. Maddox, MD Rawle A. Seupaul, MD Department (...) of Emergency Medicine University of Arkansas for Medical Sciences Little Rock, AR Results Estimated bene?t of ketamine compared to placebo for children with acute asthma exacerbation that fail standard therapy based on a single trial (N¼68). Time Pulmonary Index Score (Mean Difference) 95% Con?dence Interval 2 h 0.40 (–0.4 to 1.3) The search identi?ed 5 potential studies; only 1 trial 2 met inclusion criteria so a meta-analysis could not be performed. This trial was appro- priately powered to detect

2013 Annals of Emergency Medicine Systematic Review Snapshots

56. Randomised controlled trial: Intravenous analgesia for out-of-hospital traumatic pain in adults: ketamine gives a greater reduction in pain than morphine but causes more adverse effects

Randomised controlled trial: Intravenous analgesia for out-of-hospital traumatic pain in adults: ketamine gives a greater reduction in pain than morphine but causes more adverse effects Intravenous analgesia for out-of-hospital traumatic pain in adults: ketamine gives a greater reduction in pain than morphine but causes more adverse effects | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) traumatic pain in adults: ketamine gives a greater reduction in pain than morphine but causes more adverse effects Article Text Pain management Randomised controlled trial Intravenous analgesia for out-of-hospital traumatic pain in adults: ketamine gives a greater reduction in pain than morphine but causes more adverse effects William Paul McKay Statistics from Altmetric.com Commentary on: Jennings PA , Cameron P , Bernard S , et al . Morphine and ketamine is superior to morphine alone for out

2013 Evidence-Based Nursing

57. Adjunctive Atropine Versus Metoclopramide: Can We Reduce Ketamine-associated Vomiting in Young Children? A Prospective, Randomized, Open, Controlled Study (Abstract)

Adjunctive Atropine Versus Metoclopramide: Can We Reduce Ketamine-associated Vomiting in Young Children? A Prospective, Randomized, Open, Controlled Study Pediatric procedural sedation and analgesia (PPSA) with ketamine administration occurs commonly in the emergency department (ED). Although ketamine-associated vomiting (KAV) is a less serious complication of ketamine administration, it seems to be cumbersome and not uncommon. The authors evaluated the incidence of KAV and the prophylactic (...) effect of adjunctive atropine and metoclopramide in children receiving ketamine sedation in the ED setting.This prospective, randomized, open, controlled study was conducted in children receiving ketamine sedation in the ED of a university-affiliated, tertiary hospital with 85,000 ED visits, including 32,000 pediatric patients from October 2010 to September 2011. The primary outcome was a measure of the incidence of KAV in the ED and after discharge according to the adjunctive drug administered

2012 EvidenceUpdates Controlled trial quality: uncertain

58. Ketamine as an adjuvant to opioids for cancer pain. Full Text available with Trip Pro

Ketamine as an adjuvant to opioids for cancer pain. This is an update of the original review published in Issue 1, 2003. Ketamine is a commonly used anaesthetic agent, and in subanaesthetic doses is also given as an adjuvant to opioids for the treatment of cancer pain, particularly when opioids alone prove to be ineffective. Ketamine is known to have psychotomimetic (including hallucinogenic), urological and hepatic adverse effects.To determine the effectiveness and adverse effects of ketamine (...) as an adjuvant to opioids in the treatment of cancer pain.Studies were originally identified from MEDLINE (1966 to 2002), EMBASE (1980 to 2002), CancerLit (1966 to 2002), The Cochrane Library (Issue 1, 2001); by handsearching reference lists from review articles, trials, and chapters from standard textbooks on pain and palliative care. The manufacturer of ketamine (Pfizer Parke-Davis) provided search results from their in-house database, PARDLARS.An improved and updated search of the following was performed

2012 Cochrane

59. Ketamine for management of acute exacerbations of asthma in children. Full Text available with Trip Pro

Ketamine for management of acute exacerbations of asthma in children. Asthma is the most common chronic disease in children, and children with asthma frequently visit the paediatric emergency departments with acute exacerbations. Some of these children fail to respond to standard therapy (aerosol beta(2)-agonist with or without aerosol anticholinergic and oral or parenteral corticosteroids) for acute asthma leading to prolonged emergency department stay, hospitalisation, morbidity (e.g (...) . barotrauma, intubation) and death, albeit rarely. Ketamine may relieve bronchospasm and is a potentially promising therapy for children with acute asthma who fail to respond to standard treatment.To evaluate the efficacy of ketamine compared to placebo, no intervention or standard care for management of severe acute asthma in children who had not responded to standard therapy.We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR) and ClinicalTrials.gov. We reviewed

2012 Cochrane

60. The effect of perioperative intravenous lidocaine and ketamine on recovery after abdominal hysterectomy Full Text available with Trip Pro

The effect of perioperative intravenous lidocaine and ketamine on recovery after abdominal hysterectomy Perioperative ketamine infusion reduces postoperative pain; perioperative lidocaine infusion reduces postoperative narcotic consumption, speeds recovery of intestinal function, improves postoperative fatigue, and shortens hospital stay. However, it is unknown whether perioperative IV lidocaine and/or ketamine enhances acute functional recovery. We therefore tested the primary hypothesis (...) that perioperative IV lidocaine and/or ketamine in patients undergoing open abdominal hysterectomy improves rehabilitation as measured by a 6-minute walk distance (6-MWD) on the second postoperative morning.Women having open hysterectomy were anesthetized with sevoflurane, followed by patient-controlled morphine. Patients were factorially randomized to one of the following groups: (1) lidocaine and placebo, (2) placebo and ketamine, (3) placebo and placebo, or (4) lidocaine and ketamine. Lidocaine was given

2012 EvidenceUpdates Controlled trial quality: predicted high